Bradley Teegarden

This inventor holds 26 USPTO granted patents and 12 published patent applications, plus 5 CIPO patents and 3 EPO patents, primarily in Serotonin Receptor Modulators. Top assignees: Arena Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Tanabe Seiyaku Company, Limited. Active years: 2002-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bradley Teegarden. Retrieved from https://idiyas.com/inventor/bradley-teegarden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 12)

% Patents Active = 80.8

CIPO Patents = 5

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 7.5

ph-index = 11

Forward Citations = 254(Granted Patents)

Company Filing History:

21 out of 218

Arena Pharmaceuticals, Inc.

patents

1 out of 263

Mitsubishi Tanabe Pharma Corporation

patents

1 out of 324

Tanabe Seiyaku Company, Limited

patents

4. 3 out of 834,513

Other

patents

Years Active: 2002-2020

Loading Chart...

Areas of Expertise:

Serotonin Receptor

5-HT2A

Pyrazole Derivatives

Amines

Urea Derivatives

Cell Adhesion Inhibitors

Ethers

Secondary Amines

Primary Amines

Pharmacology

Modulators

Drug Development

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781180 - 3-phenyl-pyrazole derivatives as modulators of the 5-HTserotonin receptor useful for the treatment of disorders related thereto (2020-09-22),

2. 10450276 - Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto (2019-10-22),

3. 10351531 - [object Object] (2019-07-16),

4. 9987252 - Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto (2018-06-05),

5. 9775829 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto (2017-10-03),

6. 9732039 - Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto (2017-08-15),

7. 9434692 - [object Object] (2016-09-06),

8. 9328107 - [object Object] (2016-05-03),

9. 9273035 - [object Object] (2016-03-01),

10. 9221755 - [object Object] (2015-12-29),

11. RE45337 - Ethers, secondary amines and derivatives thereof as modulators of the 5-HTserotonin receptor useful for the treatment of disorders related thereto (2015-01-12),

12. RE45336 - Primary amines and derivatives thereof as modulators of the 5-HTserotonin receptor useful for the treatment of disorders related thereto (2015-01-12),

13. 8871797 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto (2014-10-28),

14. 8785441 - 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto (2014-07-22),

15. 8754238 - [object Object] (2014-06-17),

As someone who appreciates innovations and inventors, I would be glad to assist you in crafting an article about inventor Bradley Teegarden, based on the information provided.

Title: Innovator Spotlight: Bradley Teegarden - Pioneering Modulators of the 5-HT2A Serotonin Receptor

Introduction: Bradley Teegarden's groundbreaking work in the field of pharmaceutical compositions and their modulation of the 5-HT2A serotonin receptor has significantly impacted the treatment of various disorders related to this receptor pathway.

Latest Patents: Bradley Teegarden, based in San Diego, CA (US), holds an impressive total of 26 patents. Among his latest patents are advanced compounds such as 3-phenyl-pyrazole derivatives and ethers, which have shown promise in treating a wide range of disorders associated with the 5-HT2A serotonin receptor, including platelet aggregation, coronary artery disease, and diabetic-related disorders.

Career Highlights: Throughout his career, Bradley Teegarden has made significant contributions to the field of pharmaceuticals, particularly in the realm of serotonin receptor modulation. He has worked with esteemed companies such as Arena Pharmaceuticals, Inc., where his innovative research has paved the way for novel treatment interventions.

Collaborations: Bradley Teegarden has collaborated with top-tier professionals in the industry, including Honnappa Jayakumar and Sonja Strah-Pleynet. Together, they have synergized their expertise to advance the field of pharmaceutical compositions targeting the 5-HT2A serotonin receptor.

Conclusion: In conclusion, Bradley Teegarden's dedication to research and development in the realm of serotonin receptor modulation has revolutionized the treatment landscape for a multitude of disorders. His continued innovation and collaboration with industry experts reaffirm his status as a leading figure in the field of pharmaceutical inventions.

If you require further details or have any specific preferences, feel free to let me know.

Profile summary based on public USPTO records.